Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide

B. W. Schwab, A. M. Paldino, J. C. Arezzo, L. Flohe, T. Matthiessen, Peter Spencer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Chronic treatment of rabbits with thalidomide (3-(N-phthalimido) glutarimide) produced progressive decrements in sural nerve conduction velocity (NCV) that were unassociated with qualitative or quantitative morphological changes of nervous tissue. Three groups of eight rabbits received 100 mg/kg/day thalidomide (group I), 200 mg/kg/day supidimide (a related drug) (group II), or a carboxymethylcellulose vehicle (group III) 5 days/week for 40 weeks. At 6 months of treatment, a noninvasive determination of the mean maximum sural NCV for group I was significantly reduced relative to the conduction velocities of groups II and III. Direct measurement of conduction velocity when treatment was terminated confirmed these findings and demonstrated similar conduction deficits in proximal and distal portions of the sural nerve in group I animals. At 6 months, rabbits in group II showed a significant reduction in mean conduction velocity, and, at the termination of treatment, they displayed mean values similar to that of group III and significantly greater than that of group I. Morphological findings were unremarkable in 20 regions of the central nervous system (CNS) and the peripheral nervous system (PNS) known to display changes early in toxic neuropathies. Morphometric estimation of unmyelinated and myelinated fibers in the sural nerve at the heel revealed no between-group differences in axon diameter, fiber diameter, g-ratio (the ratio of inside/outside diameters), or internodal length. In conclusion, chronic treatment with thalidomide produces selected decrements in sural nerve function that have an unkown relationship to the poorly reversible sensory neuropathy reported in humans receiving this drug.

Original languageEnglish (US)
Pages (from-to)362-368
Number of pages7
JournalMuscle and Nerve
Volume7
Issue number5
StatePublished - 1984
Externally publishedYes

Fingerprint

Sural Nerve
Rabbits
Neural Conduction
Nerve Tissue
Carboxymethylcellulose Sodium
Heel
Poisons
Peripheral Nervous System
Pharmaceutical Preparations
Axons
Central Nervous System
supidimide
glutarimide

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Schwab, B. W., Paldino, A. M., Arezzo, J. C., Flohe, L., Matthiessen, T., & Spencer, P. (1984). Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. Muscle and Nerve, 7(5), 362-368.

Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. / Schwab, B. W.; Paldino, A. M.; Arezzo, J. C.; Flohe, L.; Matthiessen, T.; Spencer, Peter.

In: Muscle and Nerve, Vol. 7, No. 5, 1984, p. 362-368.

Research output: Contribution to journalArticle

Schwab, BW, Paldino, AM, Arezzo, JC, Flohe, L, Matthiessen, T & Spencer, P 1984, 'Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide', Muscle and Nerve, vol. 7, no. 5, pp. 362-368.
Schwab BW, Paldino AM, Arezzo JC, Flohe L, Matthiessen T, Spencer P. Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. Muscle and Nerve. 1984;7(5):362-368.
Schwab, B. W. ; Paldino, A. M. ; Arezzo, J. C. ; Flohe, L. ; Matthiessen, T. ; Spencer, Peter. / Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. In: Muscle and Nerve. 1984 ; Vol. 7, No. 5. pp. 362-368.
@article{42f2757e35b24eac85711e6391c1b1b8,
title = "Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide",
abstract = "Chronic treatment of rabbits with thalidomide (3-(N-phthalimido) glutarimide) produced progressive decrements in sural nerve conduction velocity (NCV) that were unassociated with qualitative or quantitative morphological changes of nervous tissue. Three groups of eight rabbits received 100 mg/kg/day thalidomide (group I), 200 mg/kg/day supidimide (a related drug) (group II), or a carboxymethylcellulose vehicle (group III) 5 days/week for 40 weeks. At 6 months of treatment, a noninvasive determination of the mean maximum sural NCV for group I was significantly reduced relative to the conduction velocities of groups II and III. Direct measurement of conduction velocity when treatment was terminated confirmed these findings and demonstrated similar conduction deficits in proximal and distal portions of the sural nerve in group I animals. At 6 months, rabbits in group II showed a significant reduction in mean conduction velocity, and, at the termination of treatment, they displayed mean values similar to that of group III and significantly greater than that of group I. Morphological findings were unremarkable in 20 regions of the central nervous system (CNS) and the peripheral nervous system (PNS) known to display changes early in toxic neuropathies. Morphometric estimation of unmyelinated and myelinated fibers in the sural nerve at the heel revealed no between-group differences in axon diameter, fiber diameter, g-ratio (the ratio of inside/outside diameters), or internodal length. In conclusion, chronic treatment with thalidomide produces selected decrements in sural nerve function that have an unkown relationship to the poorly reversible sensory neuropathy reported in humans receiving this drug.",
author = "Schwab, {B. W.} and Paldino, {A. M.} and Arezzo, {J. C.} and L. Flohe and T. Matthiessen and Peter Spencer",
year = "1984",
language = "English (US)",
volume = "7",
pages = "362--368",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide

AU - Schwab, B. W.

AU - Paldino, A. M.

AU - Arezzo, J. C.

AU - Flohe, L.

AU - Matthiessen, T.

AU - Spencer, Peter

PY - 1984

Y1 - 1984

N2 - Chronic treatment of rabbits with thalidomide (3-(N-phthalimido) glutarimide) produced progressive decrements in sural nerve conduction velocity (NCV) that were unassociated with qualitative or quantitative morphological changes of nervous tissue. Three groups of eight rabbits received 100 mg/kg/day thalidomide (group I), 200 mg/kg/day supidimide (a related drug) (group II), or a carboxymethylcellulose vehicle (group III) 5 days/week for 40 weeks. At 6 months of treatment, a noninvasive determination of the mean maximum sural NCV for group I was significantly reduced relative to the conduction velocities of groups II and III. Direct measurement of conduction velocity when treatment was terminated confirmed these findings and demonstrated similar conduction deficits in proximal and distal portions of the sural nerve in group I animals. At 6 months, rabbits in group II showed a significant reduction in mean conduction velocity, and, at the termination of treatment, they displayed mean values similar to that of group III and significantly greater than that of group I. Morphological findings were unremarkable in 20 regions of the central nervous system (CNS) and the peripheral nervous system (PNS) known to display changes early in toxic neuropathies. Morphometric estimation of unmyelinated and myelinated fibers in the sural nerve at the heel revealed no between-group differences in axon diameter, fiber diameter, g-ratio (the ratio of inside/outside diameters), or internodal length. In conclusion, chronic treatment with thalidomide produces selected decrements in sural nerve function that have an unkown relationship to the poorly reversible sensory neuropathy reported in humans receiving this drug.

AB - Chronic treatment of rabbits with thalidomide (3-(N-phthalimido) glutarimide) produced progressive decrements in sural nerve conduction velocity (NCV) that were unassociated with qualitative or quantitative morphological changes of nervous tissue. Three groups of eight rabbits received 100 mg/kg/day thalidomide (group I), 200 mg/kg/day supidimide (a related drug) (group II), or a carboxymethylcellulose vehicle (group III) 5 days/week for 40 weeks. At 6 months of treatment, a noninvasive determination of the mean maximum sural NCV for group I was significantly reduced relative to the conduction velocities of groups II and III. Direct measurement of conduction velocity when treatment was terminated confirmed these findings and demonstrated similar conduction deficits in proximal and distal portions of the sural nerve in group I animals. At 6 months, rabbits in group II showed a significant reduction in mean conduction velocity, and, at the termination of treatment, they displayed mean values similar to that of group III and significantly greater than that of group I. Morphological findings were unremarkable in 20 regions of the central nervous system (CNS) and the peripheral nervous system (PNS) known to display changes early in toxic neuropathies. Morphometric estimation of unmyelinated and myelinated fibers in the sural nerve at the heel revealed no between-group differences in axon diameter, fiber diameter, g-ratio (the ratio of inside/outside diameters), or internodal length. In conclusion, chronic treatment with thalidomide produces selected decrements in sural nerve function that have an unkown relationship to the poorly reversible sensory neuropathy reported in humans receiving this drug.

UR - http://www.scopus.com/inward/record.url?scp=0021240947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021240947&partnerID=8YFLogxK

M3 - Article

C2 - 6330547

AN - SCOPUS:0021240947

VL - 7

SP - 362

EP - 368

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 5

ER -